Good MorningInvestors got a dose of good news with Thursday's CPI report. The data was cooler than expected on a month-to-month and year-over-year basis, aligning with the expectation that the FOMC would cut rates at least once this year. The data from the CME suggests two cuts are possible by December, which is now the hope.
The bad news is that the CPI data was a sell-the-news event. The S&P 500 surged initially but opened weakly and moved lower throughout the day, closing with a loss of nearly 1%. The silver lining is that the S&P 500 is extended and needs a periodic correction to alleviate overbought conditions. This means the pullback, should it deepen, is reasonable considering the long-term outlook and should result in a buying opportunity soon. Featured: 100% overnight gains? (Ad) 
|
Consumer Staples | |
WD-40 Company (NASDAQ: WDFC) is a healthy, value-building company whose stock price has struggled, providing ample opportunities for investors to buy in. Hurdles remain, including high interest and inflation, but the stock price is set to rise over the coming quarters and is on track to set a new ... Read the Full Story |
|
From Our Partners | | A little known retirement strategy is helping thousands of Americans live comfortably on just 1000 to 2000 dollars per month, with no extra job required.
The approach already has 60000 users enjoying rib eye dinners, opera nights, and even Parisian style living on a modest budget.
No complicated investing or budgeting tricks are needed, just a simple method explained in a short video. | | Watch the video to learn this overlooked retirement approach today |
|
Technology | |
Investors will find that most of the market’s attention has centered on today's technology sector, particularly stocks dealing with artificial intelligence and its growing adoption throughout the global economy. For better reference, investors can dig into the VanEck Semiconductor ETF (NASDA... Read the Full Story |
|
Consumer Staples | |
PepsiCo (NASDAQ: PEP) shares have struggled with traction for the last two years as inflation, pricing pressure, consumer pushback, and economic headwinds impact results, but those days will soon end. The latest CPI report shows inflation cooling faster than expected and has the FOMC on track to... Read the Full Story |
|
From Our Partners | | Since 1950, the midterm year has been the bumpiest stretch of the four-year presidential cycle. Yet the year after every midterm, the S&P 500 finished higher all 19 times.
Investors who sold during the pre-election fear often missed the rebound that followed. Bill Poulos breaks down the pattern in a new report, The Midterm Election Playbook, including five moves to consider before and after Election Day. | | Download the free Midterm Election Playbook report today |
|
Communication Services | |
Six Flags Entertainment (NYSE: SIX) announced last week the successful completion of its merger with Cedar Fair (NYSE: FUN). The merger of these two firms in the consumer discretionary sector creates one of the largest theme park operators in North America. It will compete with firms such as the W... Read the Full Story |
|
Healthcare | |
The healthcare industry represents a substantial and dynamic market sector, presenting many opportunities for investors seeking long-term growth and stability. Factors such as the aging population, technological advances, and rising healthcare costs provide the sector with a compelling combination... Read the Full Story |
|
From Our Partners | | In May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly discussing a valuation of $1.8 to $2 trillion. That’s roughly double in about five months. And not one ordinary investor got to own a share of it.
That’s how these mega-IPOs work. The biggest gains happen privately, before the public is allowed in. By the time you can buy, the price already assumes almost everything goes right.
So I’m not chasing the IPO. I’m watching where the private investors who already doubled their money put their winnings next. | | See my #1 pick for the Claude IPO. |
|
Finance | |
The financial sector, and specifically the sector ETF Financial Select Sector SPDR Fund (NYSE: XLF), has been consolidating for several months and is now approaching a significant breakout level.
As earnings season kicks off, the sector's major players are set to report quarterly results, potent... Read the Full Story |
|
Consumer Discretionary | |
Some investors gravitate towards controversial market plays, attracted by the significant upside potential. Albemarle Co. (NYSE: ALB) deserves attention today, especially after its 34% drop since May 2024. Despite recent discouraging price action, the fundamentals of this company may signal a pote... Read the Full Story |
|
Industrials | |
Delta Air Lines (NYSE: DAL) shares lost their lift following the Q2 release, but investors should not worry. The results were weaker than expected, including decelerating growth and rising costs, but they align with the long-term outlook. The long-term outlook is for steady, normalized growth an... Read the Full Story |
|
Markets | | A dividend cut occurs when a company decides to reduce the amount that it pays out in dividends. There are many reasons why a company might do this, including financial hardship, debt reduction, or funding for new ventures. Read on to learn more about dividend cuts, what they mean, and what you may ... Read the Full Story |
|
Consumer Discretionary | |
If you have watched Kura Sushi USA (NASDAQ: KRUS) and are waiting for a good time to buy, this is it. The company is a high-quality restaurant player, growing at a solid double-digit pace, but faces headwinds impacting the share price. The headwinds are cyclical and will recede; when they do, th... Read the Full Story |
|
Friday's Early Bird Stock Of The Day ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. | | View Today's Stock Pick |
|
